SCHEMBL14923558

SCHEMBL14923558

CC(C)(C)OC(=O)N[C@@H](c1ccccc1)[C@H](Nc1nc(Cl)c(C#N)cc1F)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 1/20 0.43
▸ CTSS P25774 11/20 0.42
▸ CTSK P43235 10/20 0.42
▸ S1PR3 Q99500 1/20 0.41
▸ GABRB1 P18505 1/20 0.39
▸ GABRB2 P47870 1/20 0.39
▸ CTSB P07858 3/20 0.37
▸ CTSL P07711 2/20 0.37
▸ AAK1 Q2M2I8 2/20 0.37
▸ CYP2D6 P10635 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ NOS2 P35228 1/20 0.36
▸ SYK P43405 1/20 0.35
▸ PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19790593 0.93 TRPA1 (0.43) TRPA1CTSSCTSKS1PR3GABRB1
SCHEMBL14923546 0.93 TRPA1 (0.43) TRPA1CTSSCTSKS1PR3GABRB1
SCHEMBL3370807 0.85 TRPA1 (0.43) TRPA1CTSSCTSKS1PR3AAK1
SCHEMBL15081308 0.85 TRPA1 (0.42) TRPA1CTSSCTSKS1PR3CTSL
SCHEMBL15081497 0.84 TRPA1 (0.43) TRPA1CTSSCTSKS1PR3CTSB
SCHEMBL3346258 0.83 CTSS (0.41) TRPA1CTSSCTSKS1PR3CTSB
SCHEMBL14923454 0.83 CTSS (0.41) TRPA1CTSSCTSKS1PR3CTSB
SCHEMBL14923690 0.83 CTSS (0.43) TRPA1CTSSCTSKS1PR3GABRB1
SCHEMBL15081406 0.83 TRPA1 (0.42) TRPA1S1PR3AAK1SYK
SCHEMBL15081345 0.83 TRPA1 (0.42) TRPA1AAK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8809371-B2 — — 2014-08-19 — — US disclosed
US-8809371-B2 — — 2014-08-19 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK TRPA1 1310/4885CTSS 3435/4885CTSK 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback